GlassScriptPhysician profile
Farooq Lateef
NPI 1982802823
$8,987.18
in general payments reported to CMS, 2019-2025
31 companies · $1,332 in 2025
The $1,332 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,573 · 2020: $1,004 · 2021: $959 · 2022: $1,042 · 2023: $1,993 · 2024: $1,084 · 2025: $1,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,121 · Education: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,121.43 |
| Education | $288.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $2,954.05 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $838.88 | 2019-2025 | |
| Janssen Biotech, INC. | $797.67 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $603.54 | 2019-2024 | Olumiant |
| Abbvie INC. | $578.63 | 2019-2024 | |
| Janssen Scientific Affairs, LLC | $480.62 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $448.73 | 2019-2023 | Absorica Ld, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $368.34 | 2022-2024 | Sotyktu |
| Dermavant Sciences, INC. | $366.73 | 2022-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $302.57 | 2019-2025 | Jublia, Arazlo, Cabtreo |
| Pfizer INC. | $173.73 | 2019-2023 | |
| Amgen INC. | $139.67 | 2020-2022 | |
| Incyte Corporation | $132.80 | 2021-2023 | Opzelura |
| Celgene Corporation | $116.37 | 2019 | |
| Epi Health, LLC | $94.99 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $73.52 | 2020-2021 | |
| Galderma Laboratories, L.P. | $64.68 | 2020-2021 | |
| Genzyme Corporation | $56.60 | 2021-2023 | |
| Arcutis Biotherapeutics, INC. | $54.72 | 2023 | |
| Sandoz INC. | $53.55 | 2020 | |
| Sanofi-Aventis U.S. LLC | $50.85 | 2019-2021 | |
| Mylan Pharmaceuticals INC. | $43.33 | 2019 | |
| Dermira, INC. | $40.47 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $40.17 | 2021 | |
| Sebela Pharmaceuticals INC. | $22.51 | 2021 | |
| Almirall LLC | $19.61 | 2019 | |
| Botanix Sb INC | $19.20 | 2025 | Sofdra |
| Paratek Pharmaceuticals, INC. | $17.84 | 2021 | |
| Ucb, INC. | $16.41 | 2020 | |
| Strata Skin Sciences, INC. | $11.83 | 2022 | |
| Prugen, INC. Pharmaceuticals | $4.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farooq Lateef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.